Big Pharma's Defeat Devices
"The worse the data on the elderly got, and the worse the potential for the FDA reaction to it got, the more J&J seemed to intensify its sales effort." So writes investigative journalist Steven Brill in his chilling, meticulously researched "docuserial" America's Most Admired Lawbreaker, concerning Johnson & Johnson's efforts to market the antipsychotic Risperdal off-label -- that is, without authorization -- to seniors with dementia and children diagnosed with pediatric bipolar disorder. The series ended its fifteen-day run on The Huffington Post last week. It follows the spring publication of Brill's compelling, widely ...
Source: Science - The Huffington Post - October 5, 2015 Category: Science Source Type: news

Janssen Pharmaceuticals Accused of Hiding Risperdal's Breast Effects In Boys
Risperidone is an antipsychotic with known side effects that clinicians must balance against its benefits for a subset of autistic people. Although it can, for some autistic people, help reduce self-injurious and aggression-related behaviors, the drug can also lead to weight gain and even a movement disorder. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 29, 2015 Category: Pharmaceuticals Authors: Emily Willingham Source Type: news

Long-acting antipsychotic medication may improve treatment for schizophrenia
Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill. The problem is that many people don’t continue taking their medication once their symptoms improve. Now, a UCLA study has found that people who took a long-acting injectable for...
Source: UCLA Newsroom: Health Sciences - June 24, 2015 Category: Universities & Medical Training Source Type: news

Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression - Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG.
OBJECTIVE: The purpose of this study was to examine the satisfaction of families who participated in the Treatment of Severe Childhood Aggression (TOSCA) study. METHODS: TOSCA was a randomized clinical trial of psychostimulant plus parent training ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 24, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response - Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG.
OBJECTIVE: In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms. This secondary study explores outcome... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 22, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder - Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG.
In this study, we evaluated parent and child characteristics as predictors and moderators of response in the four-site Treatment of Severe Childhood Aggression (TOSCA) study. METHODS: A total of 168 children with severe aggression, disru... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 22, 2015 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Two drugs reduce teacher-rated anxiety, in addition to ADHD, aggression
The addition of risperidone to parent training and a stimulant also improves teachers’ assessments of anxiety and social avoidance, new research shows. Improvement in teacher-rated anxiety and social withdrawal also contributed to improvements in parent-rated disruptive behavior. Children who showed reduced anxiety also showed less disruptive behavior. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 17, 2015 Category: Science Source Type: news

Study shows 2 drugs reduce teacher-rated anxiety, in addition to ADHD, aggression
(Ohio State University Wexner Medical Center) A study led by researchers at the Nisonger Center at Ohio State's Wexner Medical Center is available online today in the Journal of Child and Adolescent Psychopharmacology and shows the addition of risperidone to parent training and a stimulant also improves teachers' assessments of anxiety and social avoidance. Improvement in teacher-rated anxiety and social withdrawal also contributed to improvements in parent-rated disruptive behavior. Children who showed reduced anxiety also showed less disruptive behavior. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2015 Category: Global & Universal Source Type: news

'Diagnosisgate' Deconstructed and Debunked
Paula Caplan has been peculiarly furious at me for more than 20 years. The enduring chip on her shoulder first formed when I didn't take seriously her written proposal that 'Delusional Dominating Personality Disorder' be considered for DSM IV. I honestly thought she had submitted 'DDPD' as a clever satire intended to illustrate how silly DSM diagnoses can sometimes be -- it made no sense to me in any other way. I misunderstood. Dr. Caplan was serious in suggesting 'DDPD' for inclusion in DSM IV and was understandably offended when I took it as a joke. Realizing my error, I apologized to Dr. Caplan, but she has apparently ...
Source: Science - The Huffington Post - March 6, 2015 Category: Science Source Type: news

Oxytocin shows promise for improving social skills in autistic mice
UCLA Dr. Daniel Geschwind People with autism spectrum disorders have difficulty with social behavior and communication, which can make it challenging to form friendships, engage in routine conversations or pick up on the social cues that are second nature to most people. Similarly, mice with symptoms of autism show little interest in interacting or socializing with other mice. A drug called risperidone has been shown to treat some symptoms of autism — including repetitive behaviors — in both humans and mice, but so far no medication has been found to help improve the ability to socialize. In a study published online b...
Source: UCLA Newsroom: Health Sciences - January 27, 2015 Category: Universities & Medical Training Source Type: news

As Risperdal Lawsuits Move Forward, Missouri Federal Judge Remands...
The Firm is representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia (male breast growth) due to their use of the medication.(PRWeb December 06, 2014)Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperidone-gynecomastia/prweb12376898.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 6, 2014 Category: Pharmaceuticals Source Type: news

Risperdal (Risperidone) - What You Need to Know
Essential information about Risperdal - generic risperidone - an antipsychotic medication approved to treat several mental disorders, including bipolar. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - November 21, 2014 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news

Antipsychotic Initiation Ups Risk for Head Injury, TBI in Alzheimer Disease
TBI injury risk up for quetiapine versus risperidone users (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Neurology, Pharmacy, Psychiatry, Geriatrics, Emergency Medicine, Journal, Source Type: news

Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression - Gadow KD, Arnold LE, Molina BS, Findling RL, Bukstein OG, Brown NV, McNamara NK, Rundberg-Rivera EV, Li X, Kipp HL, Schneider J, Farmer CA, Baker JL, Sprafkin J, Rice RR, Bangalore SS, Butter EM, Buchan-Page KA, Hurt EA, Austin AB, Grondhuis SN, Aman MG.
In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examini... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - August 30, 2014 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Case report: guanfacine overdose
Intuniv (Guanfacine) 3 out of 5 stars Prolonged Bradycardia and Hypotension Following Guanfacine Extended Release Overdose. Walton J et al. J Child Adolesc Physcopharmacol 2014 Jul 10 [Epub ahead of print] Reference  Guanfacine is a central α2-agonist with a mechanism of action similar to that of clonidine. Originally marketed as an antihypertensive agent, it is now available as an extended-release preparation (Imtuniv) for treating children ages 6-17 with attention-deficit hyperactivity disorder (ADHD). It is thought the mechanism of action in that condition may involve stimulation of α2-receptors in the prefrontal c...
Source: The Poison Review - July 18, 2014 Category: Toxicology Authors: Leon Tags: Medical ADHD attention deficit hyperactivity disorder clonidine guanfacine Source Type: news